Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome
- PMID: 7848393
- DOI: 10.1001/archsurg.1994.01420270094020
Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome
Abstract
Objective: To evaluate the effects of gender on prognostic outcome of patients with melanoma.
Design: Retrospective cohort study, including 20 years of follow-up.
Setting: Duke University Melanoma Clinic, Durham, NC, a referral center for patients with melanoma.
Patients: Patients with melanoma (N = 6383), consisting of 45% females and 55% males, obtained from a referred sample. Eligibility requirements were nonocular melanomas and white race.
Main outcome measures: Time to metastases and survival.
Results: Females with melanoma demonstrated a superior prognostic outcome over males, with a 34% survival advantage and a 28% disease-free advantage. When each of the variables of age, site, Clark's level, histologic type, and tumor thickness was explored for possible influences on prognostic outcome, female survival advantage persisted, although modified by independent variables. The greatest influence came from the variables of site, Clark's level, and Breslow's thickness. Age, specifically in premenopausal vs postmenopausal age groups, was not significant in altering females' prognostic advantage. A multivariate analysis combining the effects of all the variables resulted in females still maintaining a 22% survival advantage and a 17% disease-free advantage.
Conclusions: Females with melanoma have a significant prognostic advantage over their male counterparts that cannot be fully explained by influences from the variables of age, site, Clark's level, histology, and Breslow's thickness. This superior prognostic outcome does not appear to be associated with menstrual status. Evidence does suggest that the protective factor for females occurs at the level of metastases.
Comment in
-
Survival superiority of females with melanoma.Arch Surg. 1994 Dec;129(12):1343-4. doi: 10.1001/archsurg.1994.01420360133019. Arch Surg. 1994. PMID: 7986167 No abstract available.
Similar articles
-
A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods.Ann Surg. 1978 Dec;188(6):732-42. doi: 10.1097/00000658-197812000-00004. Ann Surg. 1978. PMID: 736651 Free PMC article.
-
Treatment Outcome and Prognostic Factors for Malignant Skin Melanoma Treated with Radical Surgery.Asian Pac J Cancer Prev. 2015;16(14):5709-14. doi: 10.7314/apjcp.2015.16.14.5709. Asian Pac J Cancer Prev. 2015. PMID: 26320440
-
Clinicopathological Features and Prognostic Factors of Malignant Melanoma: A Retrospective Analysis of Thai Patients in Ramathibodi Hospital.J Med Assoc Thai. 2015 Aug;98(8):820-7. J Med Assoc Thai. 2015. PMID: 26437541
-
Influence of gender on survival in patients with stage I malignant melanoma.J Am Acad Dermatol. 1992 Mar;26(3 Pt 2):429-40. doi: 10.1016/0190-9622(92)70068-q. J Am Acad Dermatol. 1992. PMID: 1564150 Review.
-
Pathological staging of melanoma.Methods Mol Biol. 2014;1102:325-51. doi: 10.1007/978-1-62703-727-3_17. Methods Mol Biol. 2014. PMID: 24258986 Review.
Cited by
-
Investigation of female survival benefit in metastatic melanoma.Br J Cancer. 1999 Aug;80(12):2025-33. doi: 10.1038/sj.bjc.6690637. Br J Cancer. 1999. PMID: 10471056 Free PMC article.
-
Comprehensive Analysis of the Tumor Microenvironment in Cutaneous Melanoma associated with Immune Infiltration.J Cancer. 2020 Apr 6;11(13):3858-3870. doi: 10.7150/jca.44413. eCollection 2020. J Cancer. 2020. PMID: 32328190 Free PMC article.
-
Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience.Cancer Immunol Immunother. 2015 Dec;64(12):1531-9. doi: 10.1007/s00262-015-1758-5. Epub 2015 Sep 21. Cancer Immunol Immunother. 2015. PMID: 26392296 Free PMC article. Clinical Trial.
-
In vitro effect of progesterone on human melanoma (BLM) cell growth.Int J Clin Exp Med. 2014 Nov 15;7(11):3941-53. eCollection 2014. Int J Clin Exp Med. 2014. PMID: 25550902 Free PMC article.
-
Sex differences in melanoma survival-a GEM study.JNCI Cancer Spectr. 2025 Jan 3;9(1):pkaf005. doi: 10.1093/jncics/pkaf005. JNCI Cancer Spectr. 2025. PMID: 39799507 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical